The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
/ Control Group
Age ≥ 60 years;
Scheduled for cardiac surgery involving sternotomy;
Normal blood count within the two months preceding sampling;
Patients deemed unsuitable for sampling by the surgeon performing the procedure;
Patients under legal protection measures;
Patients under judicial supervision or deprived of liberty by judicial or administrative decision;
Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).
Parallel
Epigenetic markers
Diagnostic testMethylation profiles will be analyzed and DNA regions (CpG sites) that show significant differences between healthy and pathological cells from bone marrow will be identified. These regions could serve as epigenetic markers for cells from patients with LAM, if they can be used by digital PCR. These differentially methylated CpG islands will be targeted for the design of specific primer and probe pairs for use in digital PCR. The markers will then be tested in circulating free DNA from blood.
Percentage of methylation of specific CpG sites
The methylation of circulating free DNA in plasma is quantified by measuring the percentage of methylation of specific CpG motifs analyzed in cfDNA relative to total methylation.
Click on the lead sponsor to view all of their trials.
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Lead sponsor
Institut de Recherche en Hématologie et Transplantation (IRHT)
Collaborator
